Last year, there was a 15% annual increase in the operations and surgeons want more research.

US FDA review finds no evidence linking GLP-1 receptor agonists in popular medicines like Wegovy and Zepbound to an increased risk of suicidal thoughts or behaviour ...

Popular GLP-1 and GIP medications, such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro) and liraglutide (Saxenda) ...

An Australian-led study suggests dietary intake and nutrition are being ignored in global studies of GLP-1s, which could result in malnutrition, even scurvy.

The request applies to GLP-1 RAs approved for obesity, including Novo Nordisk’s Wegovy and Saxenda and Eli Lilly’s Zepbound.

By Mariam Sunny Jan 13 (Reuters) - The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, ...

More than 4,400 lawsuits have been filed since millions of Americans embraced GLP-1 drugs like Ozempic, Wegovy and Mounjaro ...

FAT jabs could be triggering a surge in Brits needing their gallbladders removed, a shock investigation revealed today.  Leading doctors said they were doing “more and more” of such ...

After a tripling of obesity drug sales in 2025 the Swedish government has ordered a review into the surge, suspecting ...

Are GLP-1 drugs prescribed for weight loss becoming too outsized a line item for continued coverage through the state Medicaid program? That’s what Gov. Dan McKee’s fiscal year 2027 budget suggests.

Six pharmaceutical companies have applied to make a generic version of semaglutide, and competition will continue to heat up ...

Major employers and insurance companies are eliminating coverage for GLP-1 weight-loss drugs. Louisiana families now must ...